ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $136,255 | -42.2% | 25,660 | +3.7% | 0.00% | 0.0% |
Q2 2023 | $235,848 | +7.0% | 24,748 | +23.5% | 0.00% | 0.0% |
Q1 2023 | $220,352 | -24.2% | 20,032 | +2.0% | 0.00% | -50.0% |
Q4 2022 | $290,568 | -21.7% | 19,633 | +1.2% | 0.00% | -33.3% |
Q3 2022 | $371,000 | +6.3% | 19,400 | +18.3% | 0.00% | +50.0% |
Q2 2022 | $349,000 | +32.2% | 16,394 | +19.4% | 0.00% | +100.0% |
Q1 2022 | $264,000 | -13.4% | 13,733 | -6.6% | 0.00% | -50.0% |
Q4 2021 | $305,000 | -15.7% | 14,700 | -2.9% | 0.00% | 0.0% |
Q3 2021 | $362,000 | -14.4% | 15,139 | -2.3% | 0.00% | +100.0% |
Q2 2021 | $423,000 | +8.5% | 15,499 | +15.1% | 0.00% | 0.0% |
Q1 2021 | $390,000 | +15.0% | 13,471 | +11.9% | 0.00% | 0.0% |
Q4 2020 | $339,000 | +6.9% | 12,038 | +11.4% | 0.00% | -50.0% |
Q3 2020 | $317,000 | +81.1% | 10,810 | +86.5% | 0.00% | +100.0% |
Q2 2020 | $175,000 | -4.9% | 5,797 | -5.9% | 0.00% | 0.0% |
Q1 2020 | $184,000 | – | 6,159 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |